Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers
A technology for ovarian cancer and neoplasia, applied in the field of gene biomarkers, can solve the problem of unknown role of ovarian cancer
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example 1
[0057] Example 1 Identification of 25 biomarker genes of the present invention
[0058] This example is for the discovery of novel DNA methylation biomarkers for prognosis prediction and screening of ovarian cancer. Tissue samples were collected from informed and consented patients at the Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. This study was reviewed by the Institutional Review Board (Institutional Review Board) and used ovarian samples from 61 independent patients, including 49 malignant and 12 benign tissues. The samples were taken during surgery and immediately frozen in liquid nitrogen and stored at -80°C until analysis. The presence of malignant cells was confirmed by histopathological examination. A gynecologic pathologist reviewed all samples for histological evaluation. Progression free survival (PFS) was defined as the time from first surgery to progressive disease. Patients with persistent disease since first-line standard ...
example 2
[0079] Example 2 Identification of 6 biomarker genes of the present invention
[0080] Tissue samples were collected from the Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, with informed consent. This study was reviewed by the Institutional Review Board. The patients included 110 patients with epithelial ovarian cancer (EOS), 60 patients with a benign ovarian tumor and 28 patients with normal ovarian tissue. The diagnosis included histological type and grade. These samples were obtained during surgery and immediately frozen in liquid nitrogen and stored at -80°C until analysis. The presence of malignant cells was confirmed by histological examination. A gynecologic pathologist reviewed all samples for histological evaluation. Progression free survival (PFS) was defined as the time from first surgery to progressive disease. Patients with persistent disease since first-line standard therapy were excluded from PFS analysis. Overall survival (O...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com